The Effect of Broad-Spectrum Dietary Supplementation on Quality of Life, Symptom Severity, and Functioning in Multiple Sclerosis

References

• Adamo AM. 2014. Nutritional factors and aging in demyelinating diseases. Genes Nutr. 9(1):360. doi:10.1007/s12263-013-0360-8.
   PubMed Web of Science ®Google Scholar
• Ahmad H, Taylor BV, van der Mei I, Colman S, O'Leary BA, Breslin M, Palmer AJ. 2017. The impact of multiple sclerosis severity on health state utility values: evidence from Australia. Mult Scler. 23(8):1157–1166. doi:10.1177/1352458516672014.
   PubMed Web of Science ®Google Scholar
• Asche CV, Singer ME, Jhaveri M, Chung H, Miller A. 2010. All-cause health care utilization and costs associated with newly diagnosed multiple sclerosis in the United States. J Manag Care Pharm. 16(9):703–712. doi:10.18553/jmcp.2010.16.9.703.
   PubMed Web of Science ®Google Scholar
• Bagheri M, Maghsoudi Z, Fayazi S, Elahi N, Tabesh H, Majdinasab N. 2014. Several food items and multiple sclerosis: a case-control study in Ahvaz (Iran). Iran J Nurs Midwifery Res. 19(6):659–665.
   PubMedGoogle Scholar
• Balto JM, Ensari I, Hubbard EA, Khan N, Barnes JL, Motl RW. 2017. Co-occurring risk factors in multiple sclerosis. Am J Health Behav. 41(1):76–83.
   PubMed Web of Science ®Google Scholar
• Beck AT, Steer RA, Brown GK. 1996. BDI-II, Beck depression inventory: manual. San Antonio, TX: Psychological Corp. Harcourt Brace.
   Google Scholar
• Bell KM, Plon L, Bunney WE, Potkin SG. 1988. S-adenosylmethionine treatment of depression: a controlled clinical trial. Am J Psychiatry. 145(9):1110–1114. doi:10.1176/ajp.145.9.1110.
   PubMed Web of Science ®Google Scholar
• Benito-Leon J, Mitchell AJ, Rivera-Navarro J, Morales-Gonzalez JM. 2013. Impaired health-related quality of life predicts progression of disability in multiple sclerosis. Eur J Neurol. 20(1):79–86. doi:10.1111/j.1468-1331.2012.03792.x.
   PubMed Web of Science ®Google Scholar
• Brooks R. 1996. EuroQol: the current state of play. Health Policy. 37(1):53–72.
   PubMed Web of Science ®Google Scholar
• Brooks RG, Rabin R, De Charro F. 2003. The measurement and valuation of health status using EQ-5D. A European perspective. Evidence from the EuroQol BIOMED research programme. Dordrecht, South Holland: Kluwer Academic.
   Google Scholar
• Browne P, Chandraratna D, Angood C, Tremlett H, Baker C, Taylor BV, Thompson AJ. 2014. Atlas of multiple sclerosis 2013: a growing global problem with widespread inequity. Neurology. 83(11):1022–1024. doi:10.1212/WNL.0000000000000768.
   PubMed Web of Science ®Google Scholar
• Campbell JD, Ghushchyan V, Brett McQueen R, Cahoon-Metzger S, Livingston T, Vollmer T, Corboy J, Miravalle A, Schreiner T, Porter V, et al. 2014. Burden of multiple sclerosis on direct, indirect costs and quality of life: national US estimates. Mult Scler Relat Disord. 3(2):227–236. doi:10.1016/j.msard.2013.09.004.
   PubMed Web of Science ®Google Scholar
• Cella DF, Dineen K, Arnason B, Reder A, Webster KA, Karabatsos G, Chang C, Lloyd S, Steward J, Stefoski D. 1996. Validation of the functional assessment of multiple sclerosis quality of life instrument. Neurology. 47(1):129–139. doi:10.1212/wnl.47.1.129.
   PubMed Web of Science ®Google Scholar
• Dworkin RH, Bates D, Millar JH, Paty DW. 1984. Linoleic acid and multiple sclerosis: a reanalysis of three double-blind trials. Neurology. 34(11):1441–1445. doi:10.1212/wnl.34.11.1441.
   PubMed Web of Science ®Google Scholar
• Eby GA, Eby KL. 2010. Magnesium for treatment-resistant depression: a review and hypothesis. Med Hypotheses. 74(4):649–660. doi:10.1016/j.mehy.2009.10.051.
   PubMed Web of Science ®Google Scholar
• EuroQol Group. 1990. Euroqol–a new facility for the measurement of health-related quality of life. Health Policy. 16(3):199–208.
   PubMed Web of Science ®Google Scholar
• Ford HL, Gerry E, Johnson MH, Tennant A. 2001. Health status and quality of life of people with multiple sclerosis. Disabil Rehabil. 23(12):516–521.
   PubMed Web of Science ®Google Scholar
• Giordano A, Granella F, Lugaresi A, Martinelli V, Trojano M, Confalonieri P, Radice D, Solari A, Group S-T. 2011. Anxiety and depression in multiple sclerosis patients around diagnosis. J Neurol Sci. 307(1–2):86–91. doi:10.1016/j.jns.2011.05.008.
   PubMed Web of Science ®Google Scholar
• Jahromi SR, Toghae M, Jahromi MJ, Aloosh M. 2012. Dietary pattern and risk of multiple sclerosis. Iran J Neurol. 11(2):47–53.
   PubMedGoogle Scholar
• Janssens AC, Buljevac D, van Doorn PA, van der Meche FG, Polman CH, Passchier J, Hintzen RQ. 2006. Prediction of anxiety and distress following diagnosis of multiple sclerosis: a two-year longitudinal study. Mult Scler. 12(6):794–801. doi:10.1177/1352458506070935.
   PubMed Web of Science ®Google Scholar
• Kalron A. 2015. Association between perceived fatigue and gait parameters measured by an instrumented treadmill in people with multiple sclerosis: a cross-sectional study. J Neuroeng Rehabil. 12:34. doi:10.1186/s12984-015-0028-2.
   PubMed Web of Science ®Google Scholar
• Kampman MT, Steffensen LH, Mellgren SI, Jorgensen L. 2012. Effect of vitamin D3 supplementation on relapses, disease progression, and measures of function in persons with multiple sclerosis: exploratory outcomes from a double-blind randomised controlled trial. Mult Scler. 18(8):1144–1151. doi:10.1177/1352458511434607.
   PubMed Web of Science ®Google Scholar
• Kiadaliri AA, Englund M. 2016. Assessing the external validity of algorithms to estimate EQ-5D-3L from the womac. Health Qual Life Outcomes. 14(1):141. doi:10.1186/s12955-016-0547-y.
   PubMedGoogle Scholar
• Killestein J, Vennegoor A, van Golde AE, Bourez RL, Wijlens ML, Wattjes MP. 2014. Pml-iris during fingolimod diagnosed after natalizumab discontinuation. Case Rep Neurol Med. 2014:307872. doi:10.1155/2014/307872.
   PubMedGoogle Scholar
• Kurtzke JF. 1983. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 33(11):1444–1452. doi:10.1212/wnl.33.11.1444.
   PubMed Web of Science ®Google Scholar
• Lehmann-Horn K, Penkert H, Grein P, Leppmeier U, Teuber-Hanselmann S, Hemmer B, Berthele A. 2016. Pml during dimethyl fumarate treatment of multiple sclerosis: how does lymphopenia matter? Neurology. 87(4):440–441. doi:10.1212/WNL.0000000000002900.
   PubMed Web of Science ®Google Scholar
• Leong EM, Semple SJ, Angley M, Siebert W, Petkov J, McKinnon RA. 2009. Complementary and alternative medicines and dietary interventions in multiple sclerosis: what is being used in South Australia and why? Complement Ther Med. 17(4):216–223. doi:10.1016/j.ctim.2009.03.001.
   PubMed Web of Science ®Google Scholar
• Levine J, Barak Y, Gonzalves M, Szor H, Elizur A, Kofman O, Belmaker RH. 1995. Double-blind, controlled trial of inositol treatment of depression. Am J Psychiatry. 152(5):792–794. doi:10.1176/ajp.152.5.792.
   PubMed Web of Science ®Google Scholar
• Lewis JE, McDaniel HR, Agronin ME, Loewenstein DA, Riveros J, Mestre R, Martinez M, Colina N, Abreu D, Konefal J, et al. 2012. The effect of an aloe polymannose multinutrient complex on cognitive and immune functioning in alzheimer's disease. J Alzheimer's Dis. 33(2):393–406. doi:10.3233/JAD-2012-121381.
   Web of Science ®Google Scholar
• Lewis JE, Cutrono S, Melillo A, Tiozzo E, Lopez J, Adwan S, Chen L, Leonard S, Howell M, Diaz J, et al. 2014. Dietary supplementation on quality of life in adults. Agro FOOD Industry Hi Tech. 25(2):25–31.
   Google Scholar
• Lewis JE, Melillo A, Tiozzo E, Chen L, Leonard S, Howell M, Diaz J, Gonzalez K, Woolger JM, Konefal J, et al. 2014. A double-blind, randomized clinical trial of dietary supplementation on cognitive and immune functioning in healthy older adults. BMC Comp Alt Med. 14:43.
   PubMed Web of Science ®Google Scholar
• Livingston T, Fay M, Iyer R, Wells W, Pill MW. 2016. Quantifying differences in health care consumption for the management of multiple sclerosis within privately and publicly insured health care programs. J Manag Care Spec Pharm. 22(12):1385–1391. doi:10.18553/jmcp.2016.22.12.1385.
   PubMed Web of Science ®Google Scholar
• Loken-Amsrud KI, Lossius A, Torkildsen O, Holmoy T. 2015. Impact of the environment on multiple sclerosis. Tidsskr nor Laegeforen. 135(9):856–860. doi:10.4045/tidsskr.14.0751.
   PubMed Web of Science ®Google Scholar
• McDonald WI, Compston A, Edan G, Goodkin D, Hartung HP, Lublin FD, McFarland HF, Paty DW, Polman CH, Reingold SC, et al. 2001. Recommended diagnostic criteria for multiple sclerosis: guidelines from the international panel on the diagnosis of multiple sclerosis. Ann Neurol. 50(1):121–127. doi:10.1002/ana.1032.
   PubMed Web of Science ®Google Scholar
• Mehdi SM, Atlas SE, Qadir S, Musselman D, Goldberg S, Woolger JM, Corredor R, Abbas MH, Arosemena L, Caccamo S, et al. 2017. Double-blind, randomized crossover study of intravenous infusion of magnesium sulfate versus 5% dextrose on depressive symptoms in adults with treatment-resistant depression. Psychiatry Clin Neurosci. 71(3):204–211. doi:10.1111/pcn.12480.
   PubMedGoogle Scholar
• Mikula P, Nagyova I, Krokavcova M, Vitkova M, Rosenberger J, Szilasiova J, Gdovinova Z, Groothoff JW, van Dijk JP. 2015. The mediating effect of coping on the association between fatigue and quality of life in patients with multiple sclerosis. Psychol Health Med. 20(6):653–661. doi:10.1080/13548506.2015.1032310.
   PubMed Web of Science ®Google Scholar
• Neill J, Belan I, Ried K. 2006. Effectiveness of non-pharmacological interventions for fatigue in adults with multiple sclerosis, rheumatoid arthritis, or systemic lupus erythematosus: a systematic review. J Adv Nurs. 56(6):617–635. doi:10.1111/j.1365-2648.2006.04054.x.
   PubMed Web of Science ®Google Scholar
• Pittion-Vouyovitch S, Debouverie M, Guillemin F, Vandenberghe N, Anxionnat R, Vespignani H. 2006. Fatigue in multiple sclerosis is related to disability, depression and quality of life. J Neurol Sci. 243(1–2):39–45. doi:10.1016/j.jns.2005.11.025.
   PubMed Web of Science ®Google Scholar
• Pittock SJ, Mayr WT, McClelland RL, Jorgensen NW, Weigand SD, Noseworthy JH, Rodriguez M. 2004. Quality of life is favorable for most patients with multiple sclerosis: a population-based cohort study. Arch Neurol. 61(5):679–686. doi:10.1001/archneur.61.5.679.
   PubMedGoogle Scholar
• Rosenkranz T, Novas M, Terborg C. 2015. Pml in a patient with lymphocytopenia treated with dimethyl fumarate. N Engl J Med. 372(15):1476–1478. doi:10.1056/NEJMc1415408.
   PubMed Web of Science ®Google Scholar
• Sadovnick AD, Eisen K, Ebers GC, Paty DW. 1991. Cause of death in patients attending multiple sclerosis clinics. Neurology. 41(8):1193–1196. doi:10.1212/wnl.41.8.1193.
   PubMed Web of Science ®Google Scholar
• Schwab N, Schneider-Hohendorf T, Melzer N, Cutter G, Wiendl H. 2017. Natalizumab-associated pml: challenges with incidence, resulting risk, and risk stratification. Neurology. 88(12):1197–1205. doi:10.1212/WNL.0000000000003739.
   PubMed Web of Science ®Google Scholar
• Shaw JW, Johnson JA, Coons SJ. 2005. Us valuation of the EQ-5D health states: development and testing of the d1 valuation model. Med Care. 43(3):203–220.
   PubMed Web of Science ®Google Scholar
• Siegert RJ, Abernethy DA. 2005. Depression in multiple sclerosis: a review. J Neurol Neurosurg Psychiatry. 76(4):469–475. doi:10.1136/jnnp.2004.054635.
   PubMed Web of Science ®Google Scholar
• Surakka J, Romberg A, Ruutiainen J, Aunola S, Virtanen A, Karppi SL, Maentaka K. 2004. Effects of aerobic and strength exercise on motor fatigue in men and women with multiple sclerosis: a randomized controlled trial. Clin Rehabil. 18(7):737–746. doi:10.1191/0269215504cr780oa.
   PubMed Web of Science ®Google Scholar
• Tan-Kristanto S, Kiropoulos LA. 2015. Resilience, self-efficacy, coping styles and depressive and anxiety symptoms in those newly diagnosed with multiple sclerosis. Psychol Health Med. 20(6):635–645. doi:10.1080/13548506.2014.999810.
   PubMed Web of Science ®Google Scholar
• Torkildsen O, Wergeland S, Bakke S, Beiske AG, Bjerve KS, Hovdal H, Midgard R, Lilleas F, Pedersen T, Bjornara B, et al. 2012. ω-3 fatty acid treatment in multiple sclerosis (OFAMS Study): a randomized, double-blind, placebo-controlled trial. Arch Neurol. 69(8):1044–1051. doi:10.1001/archneurol.2012.283.
   PubMed Web of Science ®Google Scholar
• Trojano M, Lucchese G, Graziano G, Taylor BV, Simpson S, Lepore V, Grand’Maison F, Duquette P, Izquierdo G, Grammond P, et al. 2012. Geographical variations in sex ratio trends over time in multiple sclerosis. PLoS One. 7(10):e48078. doi:10.1371/journal.pone.0048078.
   PubMed Web of Science ®Google Scholar
• Vargas DL, Tyor WR. 2017. Update on disease-modifying therapies for multiple sclerosis. J Investig Med. 65(5):883–891. doi:10.1136/jim-2016-000339.
   PubMed Web of Science ®Google Scholar
• Varki A, Cummings RD, Esko JD, Stanley P, Hart G, Aebi M, Darvill A, Kinoshita T, Packer NH, Prestegard JJ, et al. 2015. Essentials of glycobiology. Harbor, NY: Cold Spring Harbor Laboratory Press.
   Google Scholar
• Vogt J, Paul F, Aktas O, Muller-Wielsch K, Dorr J, Dorr S, Bharathi BS, Glumm R, Schmitz C, Steinbusch H, et al. 2009. Lower motor neuron loss in multiple sclerosis and experimental autoimmune encephalomyelitis. Ann Neurol. 66(3):310–322. doi:10.1002/ana.21719.
   PubMed Web of Science ®Google Scholar
• Weinstock-Guttman B, Baier M, Park Y, Feichter J, Lee-Kwen P, Gallagher E, Venkatraman J, Meksawan K, Deinehert S, Pendergast D, et al. 2005. Low fat dietary intervention with omega-3 fatty acid supplementation in multiple sclerosis patients. Prostaglandins Leukot Essent Fatty Acids. 73(5):397–404. doi:10.1016/j.plefa.2005.05.024.
   PubMed Web of Science ®Google Scholar
• World Health Organization. 1998. The world health organization quality of life assessment (WHOQol): development and general psychometric properties. Soc Sci Med. 46(12):1569–1585.
   PubMed Web of Science ®Google Scholar
• World Health Organization, Beaglehole R, Irwin A, Prentice T. 2004. Annex table 3: Burden of disease in DALYS by cause, sex, and mortality stratum in WHO regions, estimates for 2002. In: The world health report 2004: changing history. Geneva: WHO.
   Google Scholar
• Zernicke KA, Campbell TS, Blustein PK, Fung TS, Johnson JA, Bacon SL, Carlson LE. 2013. Mindfulness-based stress reduction for the treatment of irritable bowel syndrome symptoms: a randomized wait-list controlled trial. Int J Behav Med. 20(3):385–396. doi:10.1007/s12529-012-9241-6.
   PubMed Web of Science ®Google Scholar
• Zwibel HL, Smrtka J. 2011. Improving quality of life in multiple sclerosis: an unmet need. Am J Manage Care. 17(Suppl 5):S139–S145.
   PubMedGoogle Scholar